Edition:
United States

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

23.70USD
25 May 2018
Change (% chg)

$0.56 (+2.42%)
Prev Close
$23.14
Open
$23.10
Day's High
$23.86
Day's Low
$23.10
Volume
70,777
Avg. Vol
79,367
52-wk High
$43.30
52-wk Low
$21.27

Chart for

About

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product... (more)

Overall

Beta: 1.89
Market Cap(Mil.): $1,298.70
Shares Outstanding(Mil.): 54.80
Dividend: --
Yield (%): --

Financials

  TBPH.OQ Industry Sector
P/E (TTM): -- 29.19 33.30
EPS (TTM): -5.64 -- --
ROI: -65.12 13.53 13.04
ROE: -166.54 15.25 14.90

BRIEF-Theravance Expects To Report Data From Phase 2A Study In nOH Patients By July End

* THERAVANCE BIOPHARMA TO HOST KEY OPINION LEADER EVENT FOCUSED ON THE UNMET MEDICAL NEED IN THE TREATMENT OF NEUROGENIC ORTHOSTATIC HYPOTENSION

May 17 2018

BRIEF-Theravance Biopharma Q4 Revenue $4.5 Million

* THERAVANCE BIOPHARMA, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Feb 27 2018

BRIEF-Theravance Biopharma And Mylan Announce FDA Acceptance Of New Drug Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Jan 29 2018

BRIEF-Theravance, Mylan Announce FDA Acceptance Of Marketing Application For Revefenacin

* THERAVANCE BIOPHARMA AND MYLAN ANNOUNCE FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR REVEFENACIN (TD-4208) IN ADULTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE Source text for Eikon: Further company coverage:

Jan 29 2018

BRIEF-Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​

* THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA

Nov 28 2017

Competitors

  Price Chg
Merck & Co., Inc. (MRK.N) $59.09 -0.04
The Medicines Company (MDCO.OQ) $32.91 +1.04
GlaxoSmithKline plc (GSK.L) 1,500.00 +5.80
AstraZeneca plc (AZN.L) 5,478.00 +50.00
Novartis AG (NOVN.S) CHF75.56 -0.10

Earnings vs. Estimates